Introduction
============

Interleukin 17 (IL-17) family is a subset of newly identified pro-inflammatory cytokines. The IL-17 family consists of six members, namely IL-17A, IL-17B, IL-17C, IL-17D, IL-17D, and IL-17F, according to structure similarity and order of discovery.[@b1-dddt-9-5159],[@b2-dddt-9-5159] The IL-17 receptor family includes five members: IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE.[@b1-dddt-9-5159] IL-17A and IL-17F are produced by T helper 17 (Th17) cells[@b3-dddt-9-5159] and are located just adjacent to each other on chromosome 6. Compared with other family members, IL-17A and IL-17F are most homologous in amino acid sequence.[@b4-dddt-9-5159] IL-17A is the fundamental member of IL-17 family. Evidence demonstrated that IL-17A could induce the expression of various pro-inflammatory genes like metalloproteinase,[@b5-dddt-9-5159] by activating pro-inflammatory signaling pathways. The IL-17A exerts its modulator function in both innate and adaptive immune systems, and plays an important role in the host defense against extracellular bacteria, protozoa, and fungi.[@b6-dddt-9-5159],[@b7-dddt-9-5159]

Two common single nucleotide polymorphisms in the region of IL-17A (rs2275913, G-197A) and IL-17F (rs763780, 7488T/C) have been identified and recent studies suggest that the two functional single nucleotide polymorphisms influence the susceptibility to asthma,[@b8-dddt-9-5159] arthritis,[@b9-dddt-9-5159] and even cancer.[@b10-dddt-9-5159]--[@b12-dddt-9-5159] But, the reports about IL-17A/F polymorphisms and cancer risk were controversial. Wang et al[@b11-dddt-9-5159] found IL-17A G-197A, but not IL-17F 7488T/C, polymorphism was not associated with the risk of breast cancer. On the other hand, Zhou et al[@b12-dddt-9-5159] reported both IL-17A G-197A and IL-17F 7488T/C polymorphisms were associated with the development and tumor stage of bladder cancer. It remains inconclusive whether the IL-17A G-197A and IL-17F 7488T/C polymorphisms are correlated with cancer risk or not. Therefore, we performed this meta-analysis to determine the strength of association between IL-17A G-197A and IL-17F 7488T/C polymorphisms and cancer risk by identifying and pooling eligible studies and evaluate the effect of cancer types.

Materials and methods
=====================

Selection of eligible studies
-----------------------------

To identify eligible studies, we searched PubMed, EMBASE, and Web of Science. Combination of the following key words were used: "IL17A" OR "IL17F", "rs275913" OR "rs763780" to "IL-17" OR "interleukin 17", "polymorphism" OR "single nucleotide polymorphism" OR "SNP", and "neoplasms" OR "cancer" OR "tumor" for Asians. No limitation was performed. The latest research was performed on April 13, 2015. Searching strategy is presented in the supplementary materials ([Table S1](#SD3-dddt-9-5159){ref-type="supplementary-material"}).

Inclusion and exclusion criteria
--------------------------------

Eligible studies were selected according to the following inclusion criteria: 1) case--control studies; 2) investigating the association between IL-17 polymorphisms (IL-17A G-197A and IL-17F 7488T/C) and risk of cancer; 3) cancer diagnosed by histopathology; and 4) available genotype frequencies. Studies that did not provide a detailed genotype frequency were excluded. Titles and abstracts of records were first screened and full text papers were further evaluated to confirm eligibility. Two reviewers (HW and HZ) extracted eligible studies independently according to the inclusion criteria. Disagreement between the two reviewers was discussed until consensus was achieved.

Data extraction
---------------

The following data were collected by two reviewers (HW and HZ) independently with a predesigned data-collection form: name of first author, year of publication, country where the study was performed, cancer types, study design, number of cases and controls, genotype frequency in cases and controls. According to the source of control, study design was defined as hospital-based or population-based. Though we defined the hospital-based and hospital-based study, the inclusion criteria and results were same. Sample size was judged with a threshold of 500 participants (large \>500 or small \<500). Chi-square test for goodness was used for the test of fit Hardy--Winberg equilibrium (HWE) in the controls and *P*\<0.05 was considered as disequilibrium of HWE. Two reviewers reached consensus on each item.

Statistical analysis
--------------------

Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to estimate the association strength between IL-17A G-197A and IL-17F 7488T/C polymorphisms and cancer risk. Chi-square based on Q test was used to check the statistical heterogeneity between studies, and the heterogeneity was considered significant when *P*\<0.10. The fixed-effects model (based on the Mantel--Haenszel method) and random-effects model (based on the DerSimonian--Laird method) were used to pool the data from different studies. The fixed-effects model was used when there was no significant heterogeneity; otherwise, the random-effects model was applied.[@b13-dddt-9-5159] The pooled ORs were achieved by calculating a weighted average of OR from each study. A 95% CI was used for statistical significance test and a 95% CI without 1 for OR indicating a significantly increased or reduced cancer risk. The pooled ORs were calculated for five comparison models: allele comparison (A vs a), homozygote comparison (AA vs aa), heterozygote comparison (Aa vs aa), dominant comparison (AA/Aa vs aa), and recessive comparison (AA vs Aa/aa) (A: the mutant allele, a: the wild allele; the -197A and 7488C alleles were considered as mutant alleles).

Subgroup analyses were conducted according to cancer types, study design, HWE, and sample size. Subgroup analysis was not performed for those subgroups with less than two studies. Meta-regression was performed to detect the source of heterogeneity. Publication bias was detected by Begg's test and the Egger' linear regression test, and a *P*\<0.05 was considered significant.[@b14-dddt-9-5159] Sensitivity analyses were performed to identify individual study's effect on pooled results and test the reliability of results; all *P*-values were two-sided. All statistical analyses were calculated with STATA software (version 12.0; StataCorp, College Station, TX, USA).

Results
=======

The process of study selection is shown in [Figure 1](#f1-dddt-9-5159){ref-type="fig"}. In summary, nine studies[@b10-dddt-9-5159]--[@b12-dddt-9-5159],[@b15-dddt-9-5159]--[@b20-dddt-9-5159] about IL-17A G-197A and seven studies of IL-17F 7488T/C were identified. The baseline characteristics of eligible studies are shown in [Table 1](#t1-dddt-9-5159){ref-type="table"}. Of note, all eligible studies were conducted in Asia.

Meta-analysis results
=====================

A total of nine studies, involving 3,181 cases and 4,005 controls, were available for the analysis of IL-17A G-197A. By pooling eligible studies, we found carriers of the variant -197A allele were associated with a significantly increased risk of cancer (GA/AA vs GG, OR =1.27, 95% CI: 1.15, 1.41; *P*~heterogeneity~ =0.374, [Figure 2](#f2-dddt-9-5159){ref-type="fig"}). Subgroup analyses were further conducted to evaluate the influence of predefined factors. The pooled results did not differ between different cancer types, but significant associations were most found in subgroups of population-based, large-sized studies and studies in agreement with HWE. Meta-analysis for IL-17A G-197A is shown in [Table 2](#t2-dddt-9-5159){ref-type="table"}.

A total of seven studies, including 2,262 cases and 3,261 controls, contributed to the analysis of IL-17F 7488T/C. Results showed that the homozygote of 7488CC genotype significantly increased susceptibility to cancer (CC vs TC/TT, OR =1.36, 95% CI: 0.97, 1.91, *P*~heterogeneity~ =0.875; [Figure 3](#f3-dddt-9-5159){ref-type="fig"}). Subgroup analysis indicated the IL-17F 7488T/C was only associated with risk of gastric cancer but not other cancer types. HWE results affected the pooled results, but study design did not. Meta-analysis for IL-17F 7488T/C is shown in [Table 3](#t3-dddt-9-5159){ref-type="table"}.

Meta-regression analysis
------------------------

As shown in [Tables 2](#t2-dddt-9-5159){ref-type="table"} and [3](#t3-dddt-9-5159){ref-type="table"}, significant heterogeneity was observed in several comparison models, and meta-regression analysis was performed. According to meta-regression results, sample size, cancer types, and HWE were the source of heterogeneity for both IL-17A G-197A and IL-17F 7488T/C.

Publication bias and sensitivity analysis
-----------------------------------------

Egger's test and Begg's test were performed to detect potential publication bias. The results suggested that no publication bias existed for the analysis IL-17A G-197A (Pbegg =0.466, Pegger =0.975; [Figure 4A](#f4-dddt-9-5159){ref-type="fig"}) nor the analysis of IL-17F 7488T/C (Pbegg =0.133, Pegger =0.428; [Figure 4B](#f4-dddt-9-5159){ref-type="fig"}). Individual studies' influence was determined by sensitivity analysis, which showed that the pooled results were stable and not affected by individual studies ([Figures S1](#SD1-dddt-9-5159){ref-type="supplementary-material"} and [S2](#SD2-dddt-9-5159){ref-type="supplementary-material"}).

Discussion
==========

Accumulating evidence indicates that IL-17 functions as modulator in the process of tumorigenesis and metastasis. It was found that IL-17 could induce and activate the STAT signaling pathway and promote invasion of lung cancer.[@b21-dddt-9-5159] On the other hand, IL-17 also promotes tumor invasion by modulating tumor microenvironment.[@b22-dddt-9-5159],[@b23-dddt-9-5159] Additionally, Droeser et al found that IL-17 was associated with sensitivity to platinum-chemotherapy in ovarian carcinoma.[@b24-dddt-9-5159] As a result, the expression level of IL-17 is unregulated in multiple cancers, and the level of IL-17 is correlated with progression and survival in glioblastoma and ovarian carcinoma,[@b25-dddt-9-5159],[@b26-dddt-9-5159] indicating the prognostic value of IL-17. The IL-17F 7488T/C polymorphism causes an amino acid substitution from histamine to argentine at codon 161 (H161R), which leads to a natural antagonist of wide-type IL-17. It was demonstrated by Kawaguchi et al that this functional polymorphism could influence the susceptibility to asthma.[@b8-dddt-9-5159] As for the IL-17A G-197A polymorphism, which is located in the promoter region of IL-17, it has been reported that, upon stimulation peripheral blood mononuclear cells with variant genotypes (-197AG or -197AA) secreted significantly more IL-17 than the wild type (-197GG) cells.[@b27-dddt-9-5159] This study showed that the IL-17A G-197A polymorphism could alter the promoter activity of IL-17A and cause differential production of IL-17. Taken together, these lines of evidence indicate the two polymorphisms can alter the function and production of IL-17 and it is biologically plausible that these two polymorphisms may influence susceptibility to cancer.

In the current meta-analysis, we found that both IL-17A G-197A and IL-17 7488T/C polymorphisms are associated with increased of risk of cancer. For, the IL-17A G-197A polymorphism, a significantly increased risk of cancer was found in all comparisons. While for the IL-17F 7488T/C, only carriers of the homozygote IL-17F 7488CC genotype were associated significantly increased risk of cancer and individuals with only one 7488C allele (the 7488CT genotype) showed no change cancer risk in overall analysis. One of the possible explanations is that the 7488C is a recessive allele, and in the presence of 7488T allele, the antagonizing effect of the mutated IL-17 will be compensated by the wild-type IL-17.

Subgroup analyses were performed to evaluate the effect of cancer type, study design, sample size, and HWE. In the sub-group analysis of cancer types, we found the IL-17F polymorphism increased risk of gastric cancer but no significant association was found for other cancers, indicating IL-17F may have a cancer-type-specific function. Additionally, it was also proposed that IL-17 production was associated with helicobacter pylori infection (IL-8 and IL-ref24) and IL-17 polymorphism could affect gastric cancer susceptibility by overproduction of IL-17 and subsequently overstimulation of immune system.

Heterogeneity was observed in some comparison models. We then performed a meta-regression analysis to identify the source of the heterogeneity and found that cancer types, study design, sample size, and HWE contributed to heterogeneity. But Begg's test and Egger's test showed that the pooled results were not biased. Sensitivity analysis also indicated that the results were stable and robust.

Actually, no previous meta-analysis about IL-17A and IL-17F has been performed. Our study made some significant contributions to new knowledge for the IL17 single nucleotide polymorphisms researches.[@b15-dddt-9-5159],[@b17-dddt-9-5159],[@b18-dddt-9-5159],[@b20-dddt-9-5159] Our study first reported that the variant IL-17A -197A allele and IL-17F 7488CC genotype were associated with increased risk of cancer, especially for gastric cancer. As genome-wide association studies is a powerful tool to determine the association between gene polymorphisms and cancer risk; we have searched the databases and no genome-wide association studies reported significant association between IL-17A or IL-17F polymorphism and cancer risk. Limitations of this meta-analysis should be noted. First, number of eligible studies was relatively small. Given limited number of studies, subgroup analyses for common cancer types was unavailable. In this meta-analysis, only subgroup analysis for gastric cancer was performed. Second, due to lack of individual data, we could not analyze the effect of other confounding factors, like smoking status, living habits, and so on.

Conclusion
==========

In this meta-analysis, we pooled 3,181 cases and 4,005 controls and found that carriers of the variant IL-17A-197A allele and IL-17F 7488CC genotype were associated with increased risk of cancer, especially for gastric cancer.

Supplementary materials
=======================

###### 

Sensitivity analysis of IL-17A G-197A polymorphism.

**Abbreviations:** IL, interleukin, CI, confidence interval.

###### 

Sensitivity analysis of IL-17F 7488T/C polymorphism.

**Abbreviations:** IL, interleukin, CI, confidence interval.

###### 

Searching strategy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Searching strategy for PubMed: ((interleukin-17) OR IL17) AND (((single nucleotide polymorphism) OR polymorphism) OR SNP) AND (((neoplasms)
  OR cancer) OR tumor); records identified: 32
  Searching strategy for PubMed: ((interleukin-17) OR IL17) AND (((single nucleotide polymorphism) OR polymorphism) OR SNP) AND (((neoplasms)
  OR cancer) OR tumor); records identified: 10
  Searching strategy for Web of Science: (interleukin-17) AND (polymorphism) AND (cancer); records identified from Web of Science: 21
  Searching strategy for China National Knowledge Infrastructure: ((interleukin-17) OR IL17) AND (polymorphism) OR mutation) AND (tumor) OR cancer) records identified: 27
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This study was granted by China-Japan Friendship Hospital Youth Science and Technology Excellence Project (No. 2015-QNYC-B-02) and the Research Fund of the China-Japan Friendship Hospital (No. 2014-2-MS-9).
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![Forest plot of IL-17A G-197A polymorphism and cancer risk (GA/AA vs GG).\
**Abbreviations:** IL, interleukin; OR, odds ratio; CI, confidence interval.](dddt-9-5159Fig2){#f2-dddt-9-5159}

![Forest plot of IL-17F 7488T/C polymorphism and cancer risk (CC vs TC/TT).\
**Abbreviations:** IL, interleukin; OR, odds ratio, CI, confidence interval.](dddt-9-5159Fig3){#f3-dddt-9-5159}

![Funnel plots of IL-17A G-197A (**A**) and IL-17F 7488T/C (**B**) polymorphisms.\
**Abbreviations:** IL, interleukin; OR, odds ratio.](dddt-9-5159Fig4){#f4-dddt-9-5159}

###### 

Baseline characteristics of eligible studies

  Reference                   Year   Control   Country                      Study design   Cancer types      IL-17A G-197A   IL-17F 7488T/C                                                                   
  --------------------------- ------ --------- ---------------------------- -------------- ----------------- --------------- ---------------- ----- ----- ----- ----- ----- ----- ----- ---- ----- ----- ---- -----
  Shibata[@b17-dddt-9-5159]   2009   HB        Japan                        HB             Gastric cancer    94              124              69    175   299   49    Not   221   55    4    419   100   4    Yes
  Wu[@b20-dddt-9-5159]        2010   PB        People's Republic of China   PB             Gastric cancer    210             485              250   193   371   204   Yes   540   332   55   527   214   36   No
  Wang[@b11-dddt-9-5159]      2012   PB        People's Republic of China   PB             Breast cancer     165             234              92    198   245   58    Yes   382   103   6    396   99    7    Yes
  Quan[@b18-dddt-9-5159]      2012   PB        People's Republic of China   PB             Cervical cancer   93              142              76    168   215   80    Yes   222   85    4    332   126   5    Yes
  Arisawa[@b16-dddt-9-5159]   2012   HB        Japan                        HB             Gastric cancer    112             137              84    218   293   72    Yes   NA    NA    NA   NA    NA    NA   NA
  Yuan[@b10-dddt-9-5159]      2012   HB        People's Republic of China   HB             Ovarian cancer    12              60               20    2     24    12    Not   10    69    13   2     34    2    No
  Zhang[@b19-dddt-9-5159]     2014   PB        People's Republic of China   PB             Gastric cancer    110             102              48    258   187   67    Not   209   30    21   429   53    30   No
  Zhou[@b12-dddt-9-5159]      2013   PB        People's Republic of China   PB             Bladder cancer    79              154              68    164   204   78    Yes   240   57    4    317   124   5    Yes
  Rafiei[@b15-dddt-9-5159]    2013   PB        Iran                         PB             Gastric cancer    56              61               44    78    72    21    Yes   NA    NA    NA   NA    NA    NA   NA

**Notes:** Yes means analyzed with the statistical software HWE. No means not analyzed with the statistical software HWE.

**Abbreviations:** HB, hospital-based studies; PB, population-based studies; IL, interleukin; HWE, Hardy--Winberg equilibrium; NA, no data.

###### 

Meta-analysis results for IL-17A G-197A polymorphism

                       Studies   AA vs GG                                                        GA vs GG   GA/AA vs GG                                                     AA vs GG/GA   A vs G                                                                                                                                                                                                             
  -------------------- --------- --------------------------------------------------------------- ---------- --------------------------------------------------------------- ------------- ---------------------------------------------------------------- ------- --------------------------------------------------------------- --------- --------------------------------------------------------------- -------
  Total                9         1.80 (1.40, 2.31)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.004      1.12 (1.01, 1.25)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.105         1.27 (1.15, 1.41)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}    0.374   1.64 (1.22, 2.20)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   \<0.001   1.30 (1.17, 1.45)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.021
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                         
   PB                  6         1.69 (1.32, 2.16)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.045      1.24 (1.10, 1.41)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.802         1.34 (1.19, 1.51)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}    0.635   1.50 (1.15, 1.94)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.006     1.30 (1.15, 1.48)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.039
   HB                  3         1.90 (1.01, 3.57)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.037      0.83 (0.66, 1.03)                                               0.527         1.08 (0.88, 1.33)                                                0.319   1.85 (0.94, 3.62)                                               0.003     1.24 (0.95, 1.62)                                               0.055
  Cancer types                                                                                                                                                                                                                                                                                                                                                                                               
   GC                  5         1.94 (1.32, 2.85)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.001      1.06 (0.92, 1.21)                                               0.131         1.21 (1.07, 1.38)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}    0.517   1.93 (1.18, 3.15)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   \<0.001   1.33 (1.13, 1.56)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.013
   Others              4         1.69 (1.23, 2.33)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.175      1.24 (1.04, 1.48)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.257         1.36 (1.15, 1.61)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}    0.247   1.42 (1.07, 1.89)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.139     1.27 (1.09, 1.49)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.15
  HWE                                                                                                                                                                                                                                                                                                                                                                                                        
   Yes                 6         1.80 (1.37, 2.36)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.02       1.18 (1.03, 1.34)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.057         1.303 (1.16, 1.47)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.557   1.64 (1.20, 2.26)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   \<0.001   1.32 (1.16, 1.49)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.027
   No                  3         1.60 (0.80, 3.24)                                               0.01       0.93 (0.58, 1.49)                                               0.356         1.17 (0.94, 1.44)                                                0.137   1.52 (0.70, 3.28)                                               0.001     1.22 (0.93, 1.59)                                               0.068
  Sample size                                                                                                                                                                                                                                                                                                                                                                                                
   Large               7         1.78 (1.41, 2.25)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.019      1.13 (0.96, 1.32)                                               0.071         1.26 (1.14, 1.40)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}    0.508   1.68 (1.24, 2.28)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   \<0.001   1.29 (1.18, 1.41)[\*](#tfn3-dddt-9-5159){ref-type="table-fn"}   0.132
   Small               2         1.03 (0.10, 10.27)                                              0.009      0.93 (0.39, 2.20)                                               0.213         1.36 (0.90, 2.06)                                                0.077   1.32 (0.30, 5.69)                                               0.004     1.13 (0.46, 2.74)                                               0.005

**Note:**

Statistically significant association.

**Abbreviations:** Het, *P*-value of heterogeneity; HB, hospital-based studies; PB, population-based studies; GC, gastric cancer; OR, odds ratio; CI, confidence interval; HWE, Hardy--Winberg equilibrium.

###### 

Meta-analysis results for IL-17F 7488T/C polymorphism

                       Number of Studies   CC vs TT                                                        TC vs TT   TC/CC vs TT                                                     CC vs TT/TC   C vs T                                                                                                                                                                                                            
  -------------------- ------------------- --------------------------------------------------------------- ---------- --------------------------------------------------------------- ------------- --------------------------------------------------------------- --------- --------------------------------------------------------------- ------- --------------------------------------------------------------- -------
  Total                7                   1.39 (1.03, 1.88)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.979      1.02 (0.78, 1.33)                                               0.001         1.05 (0.82, 1.35)                                               0.001     1.35 (1.00, 1.82)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.925   1.08 (0.90, 1.30)                                               0.009
  Cancer types                                                                                                                                                                                                                                                                                                                                                                                                        
   GC                  3                   1.49 (1.06, 2.10)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.937      1.29 (1.00, 1.65)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.18          1.33 (1.09, 1.64)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.24      1.36 (0.97, 1.91)                                               0.875   1.32 (1.15, 1.51)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.466
   Others              4                   1.04 (0.53, 2.05)                                               0.983      0.85 (0.61, 1.19)                                               0.059         0.87 (0.64, 1.18)                                               0.081     1.32 (0.70, 2.46)                                               0.65    0.93 (0.75, 1.15)                                               0.174
  HWE                                                                                                                                                                                                                                                                                                                                                                                                                 
   Yes                 4                   1.15 (0.61, 2.17)                                               0.868      0.92 (0.71, 1.19)                                               0.071         0.93 (0.73, 1.19)                                               0.08      1.18 (0.62, 2.21)                                               0.87    0.95 (0.77, 1.17)                                               0.133
   No                  3                   1.47 (1.04, 2.07)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.989      1.29 (0.89, 1.88)                                               0.176         1.38 (1.06, 1.79)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.254     1.41 (1.00, 1.97)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.598   1.34 (1.17, 1.55)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.635
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                                  
   PB                  5                   1.37 (1.00, 1.87)[\*](#tfn5-dddt-9-5159){ref-type="table-fn"}   0.917      1.04 (0.76, 1.43)                                               0.001         1.06 (0.79, 1.44)                                               \<0.001   1.27 (0.93, 1.74)                                               0.963   1.09 (0.83, 1.45)                                               0.923
   HB                  2                   1.69 (0.52, 5.42)                                               0.771      0.90 (0.46, 1.77)                                               0.251         1.00 (0.61, 1.61)                                               0.295     2.39 (0.86, 6.64)                                               0.664   1.07 (0.84, 1.37)                                               0.002

**Note:**

Significant association.

**Abbreviations:** OR, odds ratio; CI, confidence interval; Het, *P*-value of heterogeneity; HB, hospital-based studies; PB, population-based studies; GC, gastric cancer; HWE, Hardy--Winberg equilibrium.

[^1]: These authors contributed equally to this work
